Elevated low-density lipoprotein (LDL) cholesterol (LDL-C) is a risk factor for cardiovascular (CV) events in patients (pts) with type 2 diabetes mellitus (T2DM). However, residual CV risk remains high even in pts with well-controlled LDL-C. Studies suggest that LDL particle (LDL-P) concentration may explain this risk. A 16-week, randomized, double-blind, placebo (PBO)-controlled, multicenter study was conducted to evaluate the glucose-and lipid-lowering effect of initial combination therapy with metformin (MET)+ colesevelam (COL) in pts with early